Alnylam Pharmaceuticals (ALNY) EBT Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported EBT Margin of 18.99% for Q1 2026, up 2688.0% on a YoY basis from 0.68% in Q1 2025, and up 141.51% quarter-over-quarter from 7.86% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) EBT Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported EBT Margin for 18 years, with the latest figure at 18.99% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 2688.0% year-over-year to 18.99%; the trailing twelve-month figure through Mar 2026 stood at 12.9% (up 3063.0% YoY), and the FY2025 full-year result was 8.7%, up 2549.0% from the prior year.
- EBT Margin for Q1 2026 stood at 18.99%, up from 7.86% in the prior quarter.
- The five-year high for EBT Margin was 22.46% in Q3 2025, with the low at 153.59% in Q3 2022.
- Historically, EBT Margin has averaged 37.24% across 5 years, with a median of 21.69% in 2024.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 4474 bps — and 2023, when it soared 17367 bps.
- Alnylam Pharmaceuticals' EBT Margin stood at 61.79% in 2022, then surged by 49 bps to 31.31% in 2023, then declined by 4 bps to 32.7% in 2024, then soared by 124 bps to 7.86% in 2025, then surged by 142 bps to 18.99% in 2026.
- The last three EBT Margin figures came in at 18.99% (Q1 2026), 7.86% (Q4 2025), and 22.46% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 18.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.99% |
| Dec 31, 2025 | 7.86% |
| Sep 30, 2025 | 22.46% |
| Jun 30, 2025 | -4.57% |
| Mar 31, 2025 | -7.89% |
| Dec 31, 2024 | -32.70% |
| Sep 30, 2024 | -21.69% |
| Jun 30, 2024 | -1.69% |
| Mar 31, 2024 | -12.86% |
| Dec 31, 2023 | -31.31% |
| Sep 30, 2023 | 20.08% |
| Jun 30, 2023 | -86.03% |
| Mar 31, 2023 | -53.98% |
| Dec 31, 2022 | -61.79% |
| Sep 30, 2022 | -153.59% |
| Jun 30, 2022 | -122.18% |
| Mar 31, 2022 | -112.24% |
| Dec 31, 2021 | -100.68% |
| Sep 30, 2021 | -108.85% |
| Jun 30, 2021 | -85.39% |